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Hispanic (55.0%), enrolled in fee-for-service program (83.1%) and from an urban 
region (60.1%). OM-related antibiotic prescription claims decreased from 137,557 
in 2008 ($5,281,040) to 65,697 in 2011 ($2,010,391). The mean cost per prescription 
decreased significantly from $38.39 in 2008 to $30.60 in 2011 (p< 0.01). The most 
frequently used category of OM-related antibiotics was penicillins (215,654 claims). 
Amoxicillin was the most frequently prescribed OM-related antibiotic (48.2%), fol-
lowed by cefdinir (21.0%). However, the total outpatient prescription cost was highest 
for cefdinir ($5,736,640), followed by amoxicillin-clavulanate ($2,798,234), amoxi-
cillin ($1,914,929), azithromycin ($1,298,427), cefuroxime ($49,191), clarithromycin 
($42,959), cefpodoxime ($19,685) and ceftriaxone ($5,792). Higher age, Asian race/ 
ethnicity, female gender, fee-for-service program enrollment, Texas region, acute 
OM, amoxicillin-clavulanate, and cephalosporins were significant predictors 
(p< 0.01) of high cost prescriptions. ConClusions: Prescription claims and expen-
ditures for selected OM-related antibiotics declined between 2008 and 2011 in the 
Texas Medicaid pediatric population.
SyStemic DiSorDerS/conDitionS – clinical outcomes Studies
PSy1
SeconD Generation azoleS for ProPhylaxiS aGainSt invaSive 
funGal infection: iS voriconazole equivalent to PoSaconazole in 
haematoloGy PatientS?
Zhao F.L., Wong A.M., Ryan S., Struwig V.A.
Pfizer Australia, West Ryde, Australia
objeCtives: No randomised controlled trial has compared voriconazole and posa-
conazole directly for prophylaxis against invasive fungal infections (IFI) in high risk 
haematology patients. We performed a systematic review and indirect comparison 
of voriconazole versus posaconazole using itraconazole/fluconazole as the common 
comparator. Methods: Systematic review of full body of evidence including ran-
domised controlled trials and non-randomised studies. Adjusted indirect meta-anal-
ysis was performed using Bucher method. Non-randomised studies provide evidence 
for direct comparison between voriconazole and posaconazole. Results: A total of 
4 RCTs and 4 non-randomised studies that evaluated voriconazole or posaconazole 
were included. In these studies, two risk groups were identified on the basis of disease 
type – the haemopoetic stem cell transplant (HSCT) at risk of GVHD population, and 
acute myelogenous leukaemia or myelodysplastic syndrome (AML/MDS) population. 
The indirect estimates of risk differences (RD) were not statistically significantly dif-
ferent from 0.0; therefore indicating that voriconazole is not worse than posaconazole 
in terms of the incidence of proven or probable IFI [RD (95% CI): 0.00 (-0.06, 0.06) in 
HSCT/GVHD; 0.04 (-0.06, 0.14) in AML/MDS] and all-cause mortality rates [RD (95% 
CI): -0.00 (-0.07, 0.06) in HSCT/GVHD; 0.03 (-0.09, 0.16) in AML/MDS]. Results should be 
interpreted with caution due to heterogeneity between the risk levels of patient popu-
lations. However, the robustness of the indirect comparisons can be supported by the 
four direct non-randomised studies which consistently demonstrated similar efficacy 
of voriconazole and posaconazole and superior efficacy of voriconazole over itracona-
zole and fluconazole based on the incidence of breakthrough IFI. ConClusions: 
The clinical evidence presented in the direct and indirect comparisons consistently 
demonstrate that there are no statistically significant differences between voricona-
zole and posaconazole in terms of efficacy outcomes. Voriconazole offers an alterna-
tive option to posaconazole, which is the only therapy currently reimbursed on the 
Australian Pharmaceutical Benefits Schedule for prophylaxis of IFI.
PSy2
interchanGeability StuDy of multiSource Paracetamol 500mG 
tabletS, ProDuceD in monGolia
Ichinkhorloo T.
Fourth Health Sector Development Project, Ulaanbaatar, Mongolia
objeCtives: To define interchangeability of locally produced Paracetamol 
(Acetaminophen INN), 500mg tablets. Methods: For this purpose Paracetamol 
500mg tablets produced by 7 local manufacturers were tested. As a comparator 
product was used Panadol 500mg, produced by GlaxoSmithKline. Bioequivalence 
testing was done according to the WHO guideline, Multisource (generic) pharma-
ceutical products: guidelines on registration requirements to establish interchange-
ability, WHO Technical Report Series, No.937, 2006. Based on Biopharmaceutics 
Classification System Paracetamol tablets bioequilvalency testing was done in vitro 
through determination of dissolution. Results: In each media of pH 1.2, 4.5 and 
6.8 were tested 12 unit samples. All samples were dissolved in three media in not 
less than 85% of the labelled amount of the paracetamol in 15 minutes. According to 
the questionnaire, all manufacturers producing Paracetamol tablets answered that 
the formulation of dosage form was considered the attribute of active pharmaceu-
tical ingredient and excipients and used machinery’s specification. As criteria for 
choosing the formulation, manufacturers were used pharmacopoeial monograph, 
stability study data and dissolution results. Mongolian manufacturer’s Paracetamol 
formulations not contain excipients such as sodium bicarbonate, which is fasten-
ing the drug absorption. Three manufacturers use Povidone as a binder, same like 
comparator product. Most formulations contain Talc and Magnesium stearate as 
a lubricant mix, when comparator contains Stearic acid and Talc. All formulations 
contain starch and cellulose, their derivates. ConClusions: Paracetamol 500mg 
tablets produced by all 7 local manufacturers: LM1, LM2, LM3, LM4, LM5, LM6 and 
LM7 have dissolution more than 85% in 15 minutes in each of three media. Therefore 
the dissolution profile comparison with an f2 test is unnecessary [4]. Samples: LM1, 
LM2, LM3, LM4, LM5, LM6 and LM7 are bioequivalent and could be interchangeable 
with comparator pharmaceutical product.
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clinical efficacy of the Polyherbal ayurveDic meDicine in the 
manaGement of overweiGht
Sasikumar U.H.1, Acharya S.1, Reddy K.2, Nagappa A.N.3
cept and infliximab showed the ICER of 6,719,775 baht/QALY compared to usteki-
numab. The probability of cost-effective at threshold of 120,000 baht/QALY remained 
in favor of ustekinumab at 72.60% and presented at 13.60% for both etanercept 
and infliximab. ConClusions: Ustekinumab seems to be more cost-effective than 
etanercept and infliximab for patients with moderate-to-severe plaque psoriasis 
following biologic treatment guideline for psoriasis in Thailand.
SenSory SyStemS DiSorDerS – Patient-reported outcomes & Patient Prefer-
ence Studies
PSS10
aDherence, PreDictinG factorS anD SatiSfaction of PatientS on 
Glaucoma theraPy: finDinGS from a croSS-Sectional StuDy in Korea
Park K.H.1, Cha J.H.2
1Seoul National University College of Medicine, Seoul, South Korea, 2Pfizer Pharmaceuticals Korea 
Ltd., Seoul, South Korea
objeCtives: The aim of the study was to identify adherence and predicting fac-
tors for non-adherence and to assess the association of adherence with patient 
satisfaction of glaucoma therapy. Methods: The study population included 1,046 
glaucoma outpatients with less than two years of drug use recruited at15 eye clinics 
from March to November 2013. All patients completed a self-administered question-
naire asking about their daily use of glaucoma medications to estimate adherence 
and patients’ baseline characteristics to examine predicting factors for non-adher-
ence. Adherence was defined as patients administering the drug for ≥ 90% of pre-
scribed days. Patient satisfaction was also measured using the 14-item Treatment 
Satisfaction Questionnaire for Medication (TSQM) questionnaire which provided 
scores on four sub-scales: medication effectiveness, side effects, convenience and 
global satisfaction. The scores on TSQM are ranged 0 to 100 where higher scores indi-
cate better satisfaction. Results: Of 1,046 patients, 71.1%showed to be adherent to 
their glaucoma therapy while 28.9% accounting for 298 number of patients remained 
non-adherent. The predicting factors for non-adherence were found to be patients 
age < 65 years, and employed (p< 0.05). Non-adherent patients showed less satisfac-
tory to treatment than adherent patients as displayed by relatively lower scores in 
all sub-scales on TSQM. In the scores on the TSQM, the largest difference between 
non-adherent and adherent patients was observed on medication effectiveness 
(26.07±12.21 vs. 59.21±14.27, p< 0.001) and the smallest difference was detected in 
side effects (89.53±18.00 vs. 90.50±16.46, p= 0.405). ConClusions: About one third 
of the study population were non-adherent, and age and employment status were 
shown to influence non-adherence. Patient satisfaction was significantly associ-
ated with adherence given the lower scores on TSQM in non-adherent patients. 
Thus, these findings should be taken into account in decision making process for 
glaucoma treatment.
PSS12
utility valueS amonG myoPic PatientS in mainlanD china
Li S.
Shandong University, Jinan, China
objeCtives: To elicit utility values of adult myopic patients in mainland 
China. Methods: A valid sample of 442 myopia patients (spherical equivalent at 
least −0.5 D) aged 17–44 years, who were scheduled to undergo refractive surgery, 
were recruited. Information on time trade-off (TTO, years of life willing to sacrifice 
for treatment of myopia) and standard gamble (SG) for blindness (risk of blindness 
from therapy, willing to sacrifice for treatment of myopia) utility values, socio-
demographic and clinical data were obtained. Results: The mean utility values 
based on TTO and SG were 0.96±0.05 (95% confidence interval (CI) 0.95–0.96, median 
0.98) and 0.93±0.09 (95% CI 0.92–0.94, median 0.97), respectively. Myopic patients 
using contact lens had significantly higher TTO utility values than those wearing 
glasses (P< 0.001). There was no significant difference in the TTO and SG utility val-
ues by age, gender, occupation, educational levels, residence, reasons for refractive 
surgery, severities and duration of myopia (P> 0.05). ConClusions: The TTO and SG 
produce similar mean utility values, but there is poor agreement between results for 
individuals from the two methods. Utility values associated with myopic patients 
obtained in this study or reported in the literature appear to be higher than those 
obtained for other ophthalmic conditions.
SenSory SyStemS DiSorDerS – health care use & Policy Studies
PSS13
PreScribinG PatternS anD exPenDitureS for otitiS meDia-relateD 
antibioticS for chilDren in the texaS meDicaiD ProGram
Ma X., Lawson K.A., Richards K.M.
The University of Texas at Austin, Austin, TX, USA
objeCtives: To determine the prescribing patterns and expenditures for otitis 
media (OM)-related antibiotics in the Texas Medicaid pediatric population, and 
identify the demographic and antibiotic-related factors associated with expen-
sive prescriptions for OM-related antibiotics. Methods: This retrospective study 
used Texas Medicaid outpatient medical and prescription claims data for children 
younger than 13 years old with a diagnosis of OM (ICD-9: 381.0-382.0) and claims 
for OM-related antibiotics from January 2008 to December 2011. OM-related anti-
biotics were selected based on the guidelines proposed by the American Academy 
of Pediatrics and the American Academy of Family Physicians in 2004, and were 
classified into three categories: cephalosporins, macrolides and penicillins (amox-
icillin, amoxicillin-clavulanate). The total number (proportion) of prescriptions 
and costs were compared across selected antibiotics and categories. Generalized 
linear model was used to evaluate potential factors associated with expensive 
prescriptions. Results: 335,638 children with a mean age of 3.9 (SD= 3.2) years 
were included. The majority were boys (52.1%), younger than 3 years old (55.0%), 
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objeCtives: To study the cost effectiveness of Profofol and Thiopental Sodium 
in ICU wards as Induction Anesthetic. while perorming major surgery , anesthe-
sia administration needs an induction agent. The profofol and thiopental sodium 
are alternative as induction anestheatic agents. The efficacy and safety of both 
agents are considered almost equal.However propofol costs 248 INR (approx 4 $)
whereas Thiopental is 68INR(approx 1.2 $). The variation in the price indicates that 
thiopental is a natural choice due to price advantage. However propofol is more 
popular choice of anesthesia as it is vigorously marketed. in order to establish 
the value of thiopental the following study was carried out. Methods: The study 
was approved by Human ethics commitee, KMC hospital, Manipal. The patients 
who were going on anesthesia procedure were included in the study. However the 
choice of the anesthetic to be used is at the discretion of the anesthesiologist. 43 
patients,( propofol 34 and thiopental 19)were include in the study. The patients were 
administered EQ-5D and the quality of life was computed manually. Additional data 
on socioeconomic status was also collected in order to calculate the cost effective-
ness studies. Results: The data collected was compiled and the cost effectiveness 
of Propofol (N= 32) vs Thiopental N= 19) was calculated using EQ-5d 5L croowalk 
index calculator. THe EQ 5D score for Profofol was 0.228 ±0.298 and for thiopental 
was 0.299±0.211. the ICER was calculated using, “The average cost effectiveness = 
Net Cost/ Net Health Benefit” and it was found be -2535.21. ConClusions: It is 
found that thiopental is cost effective than propofol as ICER for the treatment is 
more than 2535.
SyStemic DiSorDerS/conDitionS – Patient-reported outcomes & Patient 
Preference Studies
PSy7
unDerStanDinG the JaPaneSe General Public’S rationale for traDeS 
in a time-traDe-off aSSeSSment for SyStemic luPuS erythematoSuS
Crawford B.1, Kim H.R.2, Wada K.1
1Adelphi Values, Tokyo, Japan, 2The University of Tokyo, Tokyo, Japan
objeCtives: There is a growing need to evaluate utilities for disorders within the 
Asian region to be used in cost-effectiveness analyses. However, there has been 
some concern about the legitimacy of direct utility elicitation among Asian subjects. 
To understand the thinking of subjects responding to a time-trade-off assessment, 
subjects were asked to describe what they considered when making their trade. 
Understanding their rationale will provide insights into the values of respond-
ents. Methods: Utility and demographic data were collected from 101 subjects 
from the general public in Tokyo. Subjects responded to six hypothetical systemic 
lupus erythematosus health states, described by six levels of severity, and provided 
their valuation of their utility through a visual analog scale and time-trade-off. One 
health state was randomly selected (excluding the anchor state) for each respondent 
to provide their rationale for their trade. Results: Respondents were comprised 
of 54 men and 47 women. Subjects provided a range of responses from concerns of 
family burden to self-preservation (“Prefer to live as long as possible”) and needing 
to finish personal commitments and “Dignity / Pride” by not wanted to ask others for 
any assistance. “Unable to bear symptoms / Prefer to die” was the most frequently 
provided response (~30%) followed by “Burden on family / others” (~20%). Subjects 
who responded to the mild health state had a tendency to respond “Able to tolerate 
symptoms” over other reasons when assessing their trade. Younger subjects were 
more likely to respond with “Hope for a cure”. ConClusions: Our study found that 
subjects were able to provide valid utility estimates from the time-trade-off. The 
rationale for trade-offs provide insights into how responses are formulated within 
an Asian country. Additional research will need to be conducted to compare these 
results to other Asian and Western countries.
PSy8
Prevalence of neuroPathic Pain in Korean PatientS ScheDuleD 
for lumbar SPine SurGery anD their health relateD quality of 
life: nationwiDe, multicenter, ProSPective, croSS-Sectional, 
obServational StuDy
Cho Y.E.1, Kim K.H.1, Kim H.J.2
1Gangnam Severance Spine Hospital, Yonsei University College of Medicine, Seoul, South Korea, 
2Pfizer Pharmaceuticals Korea Limited, Seoul, South Korea
objeCtives: The objectives of this study were to investigate the prevalence of neu-
ropathic pain(NP) among patients scheduled for lumbar spinal surgery and the rela-
tionship between health-related quality of life(HRQoL) and NP. This study also aimed 
to identify the risk factors related to NP and compare the clinical outcomes and 
impact on the HRQoL after surgical treatment between patients with and without 
NP. Methods: This study was a nationwide, multicentered, cross-sectional, observa-
tional study. It was conducted from September 2011 to May 2013, and included a total 
of 1,109 patients who were scheduled for lumbar spinal surgery from 44 spinal centers 
(both orthopaedics and neurosurgeons). Patients were diagnosed of having NP if the 
Leeds Assessment of Neuropathic Symptoms and Signs(LANSS) pain scale criteria was 
≥ 12 points. The patients were investigated to assess the differences in their clinical 
outcomes after 3 months of the surgery and were followed up with regards to pain and 
HRQoL to explore the risk factors affecting NP. Results: Of 1,109 recruited patients, 
404(36.4%) suffered from NP(mean age 62.1 years; 37.9% male) with mean LANSS score 
of 17.4±4.1, while 705(63.6%) had nociceptive pain with mean LANSS score of 6.0±3.5. 
Female and longer symptom duration were identified as risk factors for NP (OR 1.291 
and 1.003, respectively, p< 0.05). At baseline, patients with NP showed lower HRQoL 
and more severe pain compared to nociceptive pain patients. However, 3 months 
after surgical treatment, NP group showed greater improvement in pain(p= 0.087) and 
HRQoL(p= 0.029) as compared to nociceptive pain group. ConClusions: There was 
a high prevalence of NP in Korean patients scheduled for lumbar spine surgery, and 
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objeCtives: The metabolic disorder begins with signs of overweight.If un 
attended it leads to metobolic syndrome with Hypertension and Diabetes. The 
polyherbal formulation based on Ayurvedic principles used in this study in the 
management of over weight. The polyherbal formulation consisits of Triphala, 
Guduchi and Mandor basma(TGMB). Methods: Study design is randomised single 
blind compartive method. Total number of patients in both arms were 40 (20 each) 
were adminstered. The control group were adminstred Guggulu and treatement 
group recived TGMB for 45 days. The parameters observed include monitoring of 
BMI,Lipid Profile, Blood sugars. Results: Before treatement (BT)Average BMI of 
control(C)/treatement(T) group was 28.1/28;After treatement( AT), C 26.59/T 26.79; 
The total cholestrol* BT were C183.54 / T 179.93 : AT C 177.1/ T 174.4; Triglycerides* 
BT C 138.3/ T 129.6: AT C119.9 / T 116.1; HDL* BT C 44.17/ T 40.87: AT C 45.04/ T 41.13 
and Blood sugar* BT C 92 / T94.93 : AT 97.29/95.4 “ *(mg/dl). ConClusions: The 
results indicate the marginal efficacy of control group over treatement group, in 
reducing the BMI and clinical parametrs. However the TGMB was enriched with 
phytomedicines and mineral than Guggulu.
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PreScribinG PatternS anD treatment outcomeS in north inDian 
female PatientS with chronic low bacK Pain
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objeCtives: This observational study was designed to determine the prescrib-
ing pattern, improvement of pain intensity, and disability in female patients with 
CLBP. Methods: In this prospective observational study, female patients suffering 
from back pain for > 12 weeks were enrolled from a public tertiary care hospital in 
north India. Patients with failed back surgery syndrome and other concurrent pain 
conditions were excluded. Data regarding drugs prescribed, pain score assessed by 
visual analogue scale (VAS) and disability assessed by Ostwerty low back pain dis-
ability questionnaire (ODQ) collected at baseline, 3, 6 and 12 months. Effectiveness 
of pharmacotherapy assessed as improvement in pain score and disability at 3, 6 and 
12 months of follow-up. One way repeated measures anova model used to assess 
the change in pain and disability scores. Results: Total 131 female patients of 
mean age 46.2(11.2) years with BMI 22.5(5.73) were included in the study. At baseline, 
duration of CLBP found to be 24 (12-60) months. At the baseline patients on mono 
therapy 27%, Dual 45% and, multiple 28%. Overall prescribed drugs are, Pregabalin 
(82%), Amirtiptyline (64%), Duloxetine (59%), Tramadol (42%), Nortiptyline (36%), 
topical analgesics (75%), Calcium&vitamin supplements (35%), Physical exercises 
and posture advices (75%). During the period of follow-up switching of therapy 
occurred for reasons like low effectiveness and reduced pain intensity etc. When 
compared to baseline, there is a significant (P< 0.05) reduction in pain score (70 
(50-90) vs 40 (25-50)) and disability (51(42-62) vs 22 (16-32)) observed at the end of 
12 months of follow-up. Over the period of follow-ups, we found the significant 
improvement in pain (P< 0.01) and disability (P< 0.023). ConClusions: Our study 
findings concluded that pharmacological treatment, posture and physical exercises 
could be helpful in managing pain and improving of disability in CLBP patients.
SyStemic DiSorDerS/conDitionS – cost Studies
PSy5
health economic evaluation comParinG iv iron ferric 
carboxymaltoSe, iron SucroSe anD blooD tranSfuSion for 
treatment of PatientS with iron Deficiency anemia (iDa) in 
SinGaPore
Ong D.E.H.1, Hadi F.2, Stevens V.2
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objeCtives: Iron deficiency (ID) and iron deficiency anaemia (IDA) are serious 
co-morbidities that arise in several clinical situations and have significant health 
impacts. It amplifies underlying chronic conditions increasing the risk of hospitali-
sations, cost of the disease management and increase risk of mortality. Oral iron 
is mostly the first line treatment for iron deficiency, however it sometimes cannot 
be tolerated due to its side effects, responds relatively slowly, or cannot be used in 
certain chronic conditions. Intravenous iron demonstrated the trends to reduce 
transfusion needs, lower mortality risk, and shorter hospital stay. [1] [2] [3] The 
objective of the study was to estimate the direct health care costs of available intra-
venous iron in Singapore; ferric carboxymaltose (FCM), iron sucrose (IS) and blood 
transfusion for patients with IDA in Singapore. The assessment was made from 
the third party perspective represented by the Department of Medicine, National 
University Hospital Singapore. Methods: A cost-minimisation analysis compared 
1000mg FCM (1 visit, 15 minutes per visit) versus IS (5 visits, 60 minutes per visit) 
versus the current practice of 2 units of blood transfusion followed by oral adminis-
tration for 3-6 months. The cost was based on the average daily hospitalisation costs 
from the institution. Results: The utilisation of FCM increased administration 
efficiency and optimised health care resources by reducing the number of consulta-
tion visits, time to administer 1000mg of iron, and the average amount required to 
correct IDA. Administering the most cost-efficient option was estimated to save the 
health care system SGD1022 per patient (FCM vs blood transfusion). ConClusions: 
A single dose of 1,000mg FCM is more cost-efficient than IS, blood transfusion only, 
and blood transfusion combined with oral iron for the treatment of IDA in Singapore.
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